Tirzepatide.
Two pathways. One injection.
A dual GLP-1/GIP receptor agonist that targets two appetite regulation pathways instead of one. Compounded in the USA by licensed 503A pharmacies, prescribed by your clinician. No hidden overseas supply chain.
What is tirzepatide?
Tirzepatide is a dual-action compound that targets both GLP-1 and GIP receptors — two distinct pathways involved in appetite regulation, blood sugar management, and metabolic function. Where single-pathway compounds work on one receptor, tirzepatide works on two simultaneously.
It belongs to the same class as branded dual-agonist weight management medications. PepScribe's tirzepatide is compounded as an injectable formulation in the USA by licensed 503A pharmacies under a prescription from your assigned clinician — not just packaged here, actually compounded here.
Think of it as a more targeted approach — your body has multiple systems involved in hunger signaling, and tirzepatide is designed to work with two of them at the same time.
Is tirzepatide right for you?
Tirzepatide may be a good option if you're looking for the latest dual-pathway approach to weight management.
Your PepScribe clinician makes the final call on eligibility. Some patients start with semaglutide and move to tirzepatide later — your clinician will help determine the best path.
How tirzepatide works
Dual GLP-1/GIP activation
Tirzepatide activates both GLP-1 and GIP receptors. GLP-1 activation supports appetite regulation and slows gastric emptying. GIP is glucose-dependent insulinotropic polypeptide — it affects insulin secretion and has roles in adipose tissue metabolism that are still being characterized. Together, the two mechanisms appear to support weight management more than GLP-1 activation alone in head-to-head trials, though the exact contribution of GIP activation is an active research area.
Once-weekly injection
Subcutaneous injection, once per week. Your clinician starts you at a lower dose and titrates up based on your tolerability and response. Same injection routine as single-pathway GLP-1 compounds — small needle, quick process.
What to expect early on
Appetite changes are typically noticeable within the first few weeks. GI side effects during titration are similar to single-pathway GLP-1 compounds. Your clinician manages the dose schedule to minimize discomfort while supporting your goals.
What to expect
Response varies person to person. Here's a general picture of what patients commonly report over time.
Dual pathways engage
Starting dose with gradual increases. Many patients report appetite suppression that feels different from single-pathway compounds — less food noise and reduced interest in snacking. Some GI adjustment is normal during dose changes.
Metabolic momentum
GI effects generally settle. The GIP pathway's role in fat metabolism and insulin sensitivity is fully engaged alongside GLP-1. Many patients report steady, visible progress toward their weight management goals and improved energy throughout the day.
Sustaining progress
At your target dose, the focus shifts to maintaining what you've built. The dual mechanism continues to support both appetite regulation and metabolic function. Your clinician refines the protocol based on your ongoing response.
Individual results may vary. Timelines are based on commonly reported patient experiences and are not guaranteed outcomes.
Side effects — straight talk
The side effect profile is similar to single-pathway GLP-1 compounds. Most are GI-related and improve over time.
Common (may affect many patients)
- •Nausea — the most frequently reported effect, especially during dose increases
- •Diarrhea or constipation
- •Decreased appetite (this is often the intended effect)
- •Abdominal discomfort
- •Injection site reactions
Less common but worth knowing
- •Pancreatitis (rare — seek immediate medical attention for severe abdominal pain)
- •Gallbladder issues
- •Changes in vision (report any sudden vision changes to your clinician)
Important warning — thyroid C-cell tumors
Tirzepatide carries an FDA boxed warning for risk of thyroid C-cell tumors, based on the same rodent data as GLP-1 agonists. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other contraindications and cautions
- •Pregnancy or breastfeeding
- •Prior severe hypersensitivity reaction to tirzepatide
- •History of pancreatitis (relative contraindication — clinician evaluates case-by-case)
- •Type 1 diabetes (tirzepatide is not a substitute for insulin)
- •Hypoglycemia risk increases when combined with insulin or sulfonylureas
- •Rapid weight loss and reduced oral intake can raise risk of dehydration and acute kidney injury
- •Diabetic retinopathy: rapid glycemic improvement has been associated with short-term worsening of retinopathy in some patients — report any sudden vision changes
Talk to your clinician if you experience persistent or worsening side effects. Dose adjustments and timing changes often help manage GI symptoms during the titration phase.
Join the waitlist for early access pricing
We're finalizing tirzepatide pricing. Join the waitlist to lock in early access rates before we go live.
No spam. No commitment. Just early access when we launch.
Deep dives on Tirzepatide
Research-backed articles covering specific topics in depth.
See if tirzepatide is right for you.
A quick assessment to see if tirzepatide is right for you. No commitments. No pressure. Takes about 3 minutes.
See if tirzepatide is right for youResearch references
Jastreboff et al. (New England Journal of Medicine, 2022, SURMOUNT-1) — 20.9% mean weight loss at 15 mg over 72 weeks in adults with obesity without diabetes vs. 3.1% placebo. Frías et al. (NEJM, 2021, SURPASS-2) — head-to-head vs. semaglutide 1 mg in type 2 diabetes; tirzepatide produced greater HbA1c and weight reduction, with the caveat that the comparison was not against the 2.4 mg weight-management dose. Full trial summaries, contraindications, and additional citations on the tirzepatide research hub.
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. All prescriptions require approval by a licensed healthcare provider. Individual results may vary.